You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,776,331


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,776,331
Title:Methods of treating plaque psoriasis
Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
Inventor(s): Chartash; Elliot K. (Marietta, GA), Barchuk; William T. (San Diego, CA), Paulson; Susan K. (Downers Grove, IL), Valdes; Joaquin M. (Mundelein, IL), Kimball; Alexandra B. (Brookline, MA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:12/009,131
Patent Claims:1. A method of treating plaque psoriasis in a subject comprising the steps of: (i) selecting a subject who is suffering from plaque psoriasis; and (ii) subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23; thereby treating plaque psoriasis in the subject.

2. The method of claim 1, wherein said subject has had a clinical diagnosis of plaque psoriasis for at least 6 months.

3. The method of claim 1, wherein said subject has had stable plaque psoriasis for at least 2 months.

4. A method of treating plaque psoriasis in a subject comprising the steps of: (i) selecting a subject who has not had a condition selected from the group consisting of previous exposure to systemic or biologic anti-IL-12 therapy; nonplaque psoriasis; inability to discontinue topical psoriasis therapies at least 2 weeks before treatment; ultraviolet B light phototherapy at least 2 weeks before treatment; psoralen-ultraviolet-light phototherapy at least 4 weeks before treatment; systemic therapies at least 4 weeks before treatment; biologic therapies at least 12 weeks before treatment; required intake of oral or injectable corticosteroids during treatment; an exacerbation of asthma requiring hospitalization in the 10 years prior to screening; an infection or risk factors for severe infection; a history of malignancies other than successfully treated basal cell carcinoma; and a history of major immunologic reaction to an immunoglobulin G-containing agent; and (ii) subcutaneously administering to the subject about 100 mg to about 200 mg an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23; thereby treating plaque psoriasis in the subject.

5. A method of treating plaque psoriasis in a subject comprising the steps of: (i) selecting a subject who has not had vaccination with a live viral agent within 1 month; and (ii) subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23; thereby treating plaque psoriasis in the subject.

6. A method of treating plaque psoriasis in a subject comprising the steps of: (i) subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, (ii) monitoring the subject for a clinically significant abnormal laboratory result selected from the group consisting of aspartate transaminase or alanine transaminase >5 times the upper limit of normal; serum total bilirubin >3 times the upper limit of normal; serum creatinine >3 times the upper limit of normal; creatine phosphokinase >5 times the upper limit of normal; hemoglobin <8 g/dL; white blood cell count <2.times.10.sup.9/L; and platelet count <75.times.10.sup.9/L; (iii) continuing administration of the antibody, or antigen-binding portion thereof, in a subject in which the clinically significant abnormal laboratory result is not detected; thereby treating plaque psoriasis in the subject.

7. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

8. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

9. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

10. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

11. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, binds to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12.

12. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, binds to the epitope of the p40 subunit when the p40 subunit is bound to a p19 subunit of IL-23.

13. The method of any one of claims 1-6, wherein the antibody, or antigen-binding portion thereof, binds to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12 and when the p40 subunit is bound to a p19 subunit of IL-23.

14. The method of any one of claims 4-6, wherein the plaque psoriasis is chronic plaque psoriasis.

15. The method of claim 1, wherein at least a Psoriasis Area and Severity Index (PASI) 50 response is achieved in the subject.

16. The method of claim 1, wherein at least a Psoriasis Area and Severity Index (PASI) 75 response is achieved in the subject.

17. The method of claim 1, wherein at least a Psoriasis Area and Severity Index (PASI) 90 response is achieved in the subject.

18. The method of claim 1, wherein at least a Psoriasis Area and Severity Index (PASI) 100 response is achieved in the subject.

19. The method of claim 1, wherein at least a clear or minimal Physician's Global Assessment (PGA) rating is achieved in the subject.

20. The method of any one of claims 15-18, wherein the PASI response is achieved by week 12 following initial administration of the antibody, or antigen-binding portion thereof, to the subject.

21. The method of claim 19, wherein the PGA rating is achieved by week 12 following initial administration of the antibody, or antigen-binding portion thereof, to the subject.

22. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 90 response for a period of at least about 12 weeks following initial administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

23. The method of claim 22, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

24. The method of claim 22, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

25. The method of claim 22, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

26. The method of claim 22, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

27. The method of claim 22, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

28. The method of claim 22, wherein the plaque psoriasis is chronic plaque psoriasis.

29. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 75 response for a period of at least about 12 weeks following initial administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

30. The method of claim 29, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

31. The method of claim 29, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

32. The method of claim 29, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

33. The method of claim 29, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

34. The method of claim 29, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

35. The method of claim 29, wherein the plaque psoriasis is chronic plaque psoriasis.

36. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject exhibits an improved Psoriasis Area and Severity Index (PASI) score by about 8 weeks following initial administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

37. The method of claim 36, wherein the subject exhibits an improved PASI score by about 4 weeks following initial administration of the antibody, or antigen binding portion thereof.

38. The method of claim 36, wherein the subject exhibits an improved PASI score by about 2 weeks following initial administration of the antibody, or antigen binding portion thereof.

39. The method of claim 36, wherein the subject exhibits an improved PASI score by about 1 week following initial administration of the antibody, or antigen binding portion thereof.

40. The method of claim 36, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

41. The method of claim 36, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

42. The method of claim 36, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

43. The method of claim 36, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

44. The method of claim 36, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

45. The method of claim 36, wherein the plaque psoriasis is chronic plaque psoriasis.

46. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 50 response for a period of at least about 12 weeks following initial administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

47. The method of claim 46, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

48. The method of claim 46, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

49. The method of claim 46, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

50. The method of claim 46, wherein the plaque psoriasis is chronic plaque psoriasis.

51. The method of claim 46, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

52. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 50 response for a period of at least about 12 weeks following discontinuation of administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

53. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 75 response for a period of at least about 12 weeks following discontinuation of administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

54. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a Psoriasis Area and Severity Index (PASI) 90 response for a period of at least about 12 weeks following discontinuation of administration of the antibody, or antigen-binding portion thereof, thereby treating plaque psoriasis in the subject.

55. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered for at least about 12 weeks.

56. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

57. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

58. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

59. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

60. The method of any one of claims 52-54, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

61. The method of any one of claims 52-54, wherein the plaque psoriasis is chronic plaque psoriasis.

62. A method of treating plaque psoriasis in a subject comprising subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody which binds to human IL-12 and human IL-23 on a biweekly dosing regimen, such that plaque psoriasis is treated.

63. The method of claim 62, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

64. The method of claim 62, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

65. A method of treating plaque psoriasis in a subject comprising the steps of: (i) selecting a subject who is suffering from chronic plaque psoriasis affecting about .gtoreq.20% body surface area; and (ii) subcutaneously administering to the subject about 100 mg to about 200 mg of an antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12 and/or IL-23; thereby treating chronic plaque psoriasis in the subject.

66. The method of claim 65, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

67. The method of claim 65, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.